Statins and Risk of Cholangiocarcinoma: A Systematic Review and Meta-analysis

Karn Wijarnpreecha; Elizabeth S Aby; Hassan Ghoz; Wisit Cheungpasitporn; Frank J Lukens; Denise M Harnois; Patompong Ungprasert

doi:10.15403/jgld-2990

Statins and Risk of Cholangiocarcinoma: A Systematic Review and Meta-analysis

Karn Wijarnpreecha
, Elizabeth S Aby
, Hassan Ghoz
, Wisit Cheungpasitporn
, Frank J Lukens
, Denise M Harnois
, Patompong Ungprasert

Medicine - Gastro, Hepatology, Nutrition Division

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

BACKGROUND AND AIMS: The use of statins has been shown to be associated with a decreased risk of cholangiocarcinoma (CCA) in many studies although the results have been inconsistent. We conducted this systematic review and meta-analysis to further investigate this possible association by identifying all relevant studies and combining their results together.

METHODS: A comprehensive literature review was conducted utilizing the MEDLINE and EMBASE databases through March 2020 to identify all studies that compared the risk of CCA among individuals who use statins with individuals who do not use statins. Effect estimates from each study were extracted and combined using the random-effect, generic inverse variance method of DerSimonian and Laird.

RESULTS: A total of seven studies with 6,251,187 participants fulfilled the eligibility criteria and were included in this meta-analysis. The pooled analysis found a significantly decreased risk of CCA among individuals who use statins compared with individuals who do not use statins with the pooled odds ratio of 0.68 (95% CI: 0.52-0.89; I 2 96%).

CONCLUSIONS: The current systematic review and meta-analysis found a significant association between the use of statins and a decreased risk of CCA.

Original language	English (US)
Pages (from-to)	629-635
Number of pages	7
Journal	Journal of Gastrointestinal and Liver Diseases
Volume	29
Issue number	4
DOIs	https://doi.org/10.15403/jgld-2990
State	Published - Dec 13 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Bile Duct Neoplasms/etiology
Cholangiocarcinoma/etiology
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use

PubMed: MeSH publication types

Journal Article
Meta-Analysis
Systematic Review

Publisher link

10.15403/jgld-2990

Find It

Find It at U of M Libraries

Cite this

@article{66d8b18ac173451fbbcabb7a0e3c1174,

title = "Statins and Risk of Cholangiocarcinoma: A Systematic Review and Meta-analysis",

abstract = "BACKGROUND AND AIMS: The use of statins has been shown to be associated with a decreased risk of cholangiocarcinoma (CCA) in many studies although the results have been inconsistent. We conducted this systematic review and meta-analysis to further investigate this possible association by identifying all relevant studies and combining their results together.METHODS: A comprehensive literature review was conducted utilizing the MEDLINE and EMBASE databases through March 2020 to identify all studies that compared the risk of CCA among individuals who use statins with individuals who do not use statins. Effect estimates from each study were extracted and combined using the random-effect, generic inverse variance method of DerSimonian and Laird.RESULTS: A total of seven studies with 6,251,187 participants fulfilled the eligibility criteria and were included in this meta-analysis. The pooled analysis found a significantly decreased risk of CCA among individuals who use statins compared with individuals who do not use statins with the pooled odds ratio of 0.68 (95\% CI: 0.52-0.89; I 2 96\%).CONCLUSIONS: The current systematic review and meta-analysis found a significant association between the use of statins and a decreased risk of CCA.",

keywords = "Bile Duct Neoplasms/etiology, Cholangiocarcinoma/etiology, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use",

author = "Karn Wijarnpreecha and Aby, \{Elizabeth S\} and Hassan Ghoz and Wisit Cheungpasitporn and Lukens, \{Frank J\} and Harnois, \{Denise M\} and Patompong Ungprasert",

year = "2020",

month = dec,

day = "13",

doi = "10.15403/jgld-2990",

language = "English (US)",

volume = "29",

pages = "629--635",

journal = "Journal of Gastrointestinal and Liver Diseases",

issn = "1841-8724",

publisher = "Romanian Society of Gastroenterology",

number = "4",

}

TY - JOUR

T1 - Statins and Risk of Cholangiocarcinoma

T2 - A Systematic Review and Meta-analysis

AU - Wijarnpreecha, Karn

AU - Aby, Elizabeth S

AU - Ghoz, Hassan

AU - Cheungpasitporn, Wisit

AU - Lukens, Frank J

AU - Harnois, Denise M

AU - Ungprasert, Patompong

PY - 2020/12/13

Y1 - 2020/12/13

N2 - BACKGROUND AND AIMS: The use of statins has been shown to be associated with a decreased risk of cholangiocarcinoma (CCA) in many studies although the results have been inconsistent. We conducted this systematic review and meta-analysis to further investigate this possible association by identifying all relevant studies and combining their results together.METHODS: A comprehensive literature review was conducted utilizing the MEDLINE and EMBASE databases through March 2020 to identify all studies that compared the risk of CCA among individuals who use statins with individuals who do not use statins. Effect estimates from each study were extracted and combined using the random-effect, generic inverse variance method of DerSimonian and Laird.RESULTS: A total of seven studies with 6,251,187 participants fulfilled the eligibility criteria and were included in this meta-analysis. The pooled analysis found a significantly decreased risk of CCA among individuals who use statins compared with individuals who do not use statins with the pooled odds ratio of 0.68 (95% CI: 0.52-0.89; I 2 96%).CONCLUSIONS: The current systematic review and meta-analysis found a significant association between the use of statins and a decreased risk of CCA.

AB - BACKGROUND AND AIMS: The use of statins has been shown to be associated with a decreased risk of cholangiocarcinoma (CCA) in many studies although the results have been inconsistent. We conducted this systematic review and meta-analysis to further investigate this possible association by identifying all relevant studies and combining their results together.METHODS: A comprehensive literature review was conducted utilizing the MEDLINE and EMBASE databases through March 2020 to identify all studies that compared the risk of CCA among individuals who use statins with individuals who do not use statins. Effect estimates from each study were extracted and combined using the random-effect, generic inverse variance method of DerSimonian and Laird.RESULTS: A total of seven studies with 6,251,187 participants fulfilled the eligibility criteria and were included in this meta-analysis. The pooled analysis found a significantly decreased risk of CCA among individuals who use statins compared with individuals who do not use statins with the pooled odds ratio of 0.68 (95% CI: 0.52-0.89; I 2 96%).CONCLUSIONS: The current systematic review and meta-analysis found a significant association between the use of statins and a decreased risk of CCA.

KW - Bile Duct Neoplasms/etiology

KW - Cholangiocarcinoma/etiology

KW - Humans

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use

U2 - 10.15403/jgld-2990

DO - 10.15403/jgld-2990

M3 - Article

C2 - 33331334

SN - 1841-8724

VL - 29

SP - 629

EP - 635

JO - Journal of Gastrointestinal and Liver Diseases

JF - Journal of Gastrointestinal and Liver Diseases

IS - 4

ER -

Statins and Risk of Cholangiocarcinoma: A Systematic Review and Meta-analysis

Abstract

UN SDGs

Keywords

PubMed: MeSH publication types

Publisher link

Find It

Fingerprint

Cite this